Patents by Inventor John Telford
John Telford has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10428121Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: November 7, 2017Date of Patent: October 1, 2019Assignees: Novartis AG, J. Craig Venter Institute, Inc.Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
-
Publication number: 20180094033Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: ApplicationFiled: November 7, 2017Publication date: April 5, 2018Inventors: John TELFORD, Vega MASIGNANI, Maria SCARSELLI, Guido GRANDI, Herve TETTELIN, Claire FRASER
-
Publication number: 20180036402Abstract: A method of immunization against Group B Streptococcus infection, using an immunogenic composition conjugates of GBS capsular saccharide conjugated to carrier proteins.Type: ApplicationFiled: September 15, 2017Publication date: February 8, 2018Applicant: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco BERTI, Mario CONTORNI, Paolo COSTANTINO, Oretta FINCO, Guido GRANDI, Domenico MAIONE, John TELFORD
-
Patent number: 9840538Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: June 26, 2015Date of Patent: December 12, 2017Assignees: Novartis AG, J. Craig Venter Institute, Inc.Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
-
Patent number: 9738693Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: May 26, 2016Date of Patent: August 22, 2017Assignees: Novartis AG, J. Craig Venter Institute, Inc.Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
-
Publication number: 20160264632Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: ApplicationFiled: May 26, 2016Publication date: September 15, 2016Inventors: John TELFORD, Vega MASIGNANI, Maria SCARSELLI, Guido GRANDI, Herve TETTELIN, Claire FRASER
-
Publication number: 20150368304Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: ApplicationFiled: June 26, 2015Publication date: December 24, 2015Inventors: John TELFORD, Vega MASIGNANI, Maria SCARSELLI, Guido GRANDI, Herve TETTELIN, Claire FRASER
-
Publication number: 20150283232Abstract: The invention provides an immunogenic composition comprising: (a) a conjugate that is a capsular saccharide from GBS serotype I1 conjugated to a carrier protein; (b) a conjugate that is a capsular saccharide from GBS serotype Ib conjugated to a carrier protein; and (c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunizing a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunized with a diphtheria toxoid or derivative thereof.Type: ApplicationFiled: March 19, 2015Publication date: October 8, 2015Inventors: Francesco BERTI, Mario CONTORNI, Paolo COSTANTINO, Oretta FINCO, Guido Grandi, Domenico MAIONE, John Telford
-
Patent number: 9056912Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: GrantFiled: September 9, 2013Date of Patent: June 16, 2015Assignee: Novartis Vaccines and Diagnostics, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Patent number: 8945589Abstract: This application relates to Group B Streptococcus (“GBS”) vaccines comprising combinations of GBS polypeptide antigens where the polypeptides contribute to the immunological response in a recipient. Preferably, the compositions of the invention comprise a combination of two or more GBS antigens, wherein said combination includes GBS 80 or a fragment thereof. In one embodiment, the combination may consist of two to thirteen GBS antigens selected from an antigen group consisting of GBS 80, GBS 91, GBS 104, GBS 184, GBS 276, GBS 305, GBS 322, GBS 330, GBS 338, GBS 361, GBS 404, GBS 690, and GBS 691.Type: GrantFiled: September 15, 2004Date of Patent: February 3, 2015Assignee: Novartis Vaccines and Diagnostics, SRLInventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Domenico Maione
-
Patent number: 8778358Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.Type: GrantFiled: October 18, 2010Date of Patent: July 15, 2014Assignee: Novartis Vaccines and Diagnostics, Inc.Inventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Cira Daniela Rinaudo, Domenico Maione
-
Publication number: 20140037671Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: ApplicationFiled: September 9, 2013Publication date: February 6, 2014Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Publication number: 20140004140Abstract: This application relates to improved Group B Streptococcus (“GBS”) saccharide-based vaccines comprising combinations of GBS polysaccharides with polypeptide antigens, and vice versa, such that the polypeptide and the saccharide each contribute to the immunological response in a recipient. The combination is particularly advantageous where the saccharide and polypeptide are from different GBS serotypes. The combined antigens may be present as a simple combination where separate saccharide and polypeptide antigens are administered together, or they may be present as a conjugated combination, where the saccharide and polypeptide antigens are covalently linked to each other.Type: ApplicationFiled: September 6, 2013Publication date: January 2, 2014Applicant: Novartis Vaccines and Diagnostics, Inc.Inventors: Rino Rappuoli, John Telford, Guido Grandi
-
Publication number: 20130273091Abstract: The invention provides an immunogenic composition comprising: a) a conjugate that is a capsular saccharide from GBS serotype 1a conjugated to a carrier protein; b) a conjugate that is a capsular saccharide from GBS serotype 1b conjugated to a carrier protein; and c) a conjugate that is a capsular saccharide from GBS serotype III conjugated to a carrier protein. The invention also provides a method for immunising a patient against infection by GBS comprising the step of administering to the patient a conjugate that is a capsular saccharide from GBS conjugated to a diphtheria toxoid or derivative thereof, wherein the patient has been pre-immunised with a diphtheria toxoid or derivative thereof.Type: ApplicationFiled: September 16, 2011Publication date: October 17, 2013Inventors: Francesco Berti, Mario Contorni, Paolo Costantino, Oretta Finco, Guido Grandi, Domenico Maione, John Telford
-
Patent number: 8529913Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: GrantFiled: March 2, 2012Date of Patent: September 10, 2013Assignee: Novartis Vaccines and Diagnostics, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Publication number: 20130129740Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: ApplicationFiled: August 30, 2012Publication date: May 23, 2013Applicants: J. Craig Venter Institute, Novartis Vaccines and Diagnostics, Inc.Inventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Hervé Tettelin, Claire Fraser
-
Patent number: 8431139Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: May 16, 2006Date of Patent: April 30, 2013Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter InstituteInventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser
-
Publication number: 20120315292Abstract: The invention includes a GAS antigen, GAS 40, which is particularly suitable for use either alone or in combinations with additional GAS antigens, such as GAS 117, GAS 130, GAS 277, GAS 236, GAS 40, GAS 389, GAS 504, GAS 509, GAS 366, GAS 159, GAS 217, GAS 309, GAS 372, GAS 039, GAS 042, GAS 058, GAS 290, GAS 511, GAS 533, GAS 527, GAS 294, GAS 253, GAS 529, GAS 045, GAS 095, GAS 193, GAS 137, GAS 084, GAS 384, GAS 202, and GAS 057.Type: ApplicationFiled: March 2, 2012Publication date: December 13, 2012Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, SRLInventors: Guido Grandi, John Telford, Giuliano Bensi
-
Publication number: 20120207778Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences.Type: ApplicationFiled: February 16, 2012Publication date: August 16, 2012Applicants: J. CRAIG VENTER INSTITUTE, INC., NOVARTIS VACCINES AND DIAGNOSTICS S.R.L.Inventors: John Telford, Vega Masignani, Immaculada Margarit Y Ros, Guido Grandi, Claire Fraser, Hervé Tettelin
-
Patent number: 8137673Abstract: The invention provides proteins from group B streptococcus (Streptococcus agalactiae) and group A streptococcus (Streptococcus pyogenes), including amino acid sequences and the corresponding nucleotide sequences. Data are given to show that the proteins are useful antigens for vaccines, immunogenic compositions, and/or diagnostics. The proteins are also targets for antibiotics.Type: GrantFiled: May 16, 2006Date of Patent: March 20, 2012Assignees: Novartis Vaccines and Diagnostics, Inc., J. Craig Venter InstituteInventors: John Telford, Vega Masignani, Maria Scarselli, Guido Grandi, Herve Tettelin, Claire Fraser